company-logo

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences Dividend Announcement

Cellectar Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on Cellectar Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Cellectar Biosciences Dividend History

Cellectar Biosciences Dividend Yield

Cellectar Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cellectar Biosciences stock? Use our calculator to estimate your expected dividend yield:

Cellectar Biosciences Financial Ratios

P/E ratio-1.74
PEG ratio0.11
P/B ratio6.13
ROE-732.97%
Payout ratio0.00%
Current ratio1.84
Quick ratio1.84
Cash Ratio1.71

Cellectar Biosciences Dividend FAQ

Does Cellectar Biosciences stock pay dividends?
Cellectar Biosciences does not currently pay dividends to its shareholders.
Has Cellectar Biosciences ever paid a dividend?
No, Cellectar Biosciences has no a history of paying dividends to its shareholders. Cellectar Biosciences is not known for its dividend payments.
Why doesn't Cellectar Biosciences pay dividends?
There are several potential reasons why Cellectar Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Cellectar Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Cellectar Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Cellectar Biosciences a dividend aristocrat?
Cellectar Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Cellectar Biosciences a dividend king?
Cellectar Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Cellectar Biosciences a dividend stock?
No, Cellectar Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Cellectar Biosciences stocks?
To buy Cellectar Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Cellectar Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.